JPMorgan analyst Casey Woodring raised the firm’s price target on Illumina (ILMN) to $130 from $105 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target raised to $110 from $100 at Barclays
- Illumina, MyOme announces collaboration, investment by Illumina into MyOme
- Illumina Completes $500M Notes Offering for Expansion
- Cathie Wood Buys Nvidia, ACHR and Crypto Stocks, Offloads AMD, EXAS
- Illumina Announces $500M Notes Issuance Agreement